Nature Communications (Jun 2022)
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
- John Hilton,
- Karen Gelmon,
- Philippe L. Bedard,
- Dongsheng Tu,
- Hong Xu,
- Anna V. Tinker,
- Rachel Goodwin,
- Scott A. Laurie,
- Derek Jonker,
- Aaron R. Hansen,
- Zachary W. Veitch,
- Daniel J. Renouf,
- Linda Hagerman,
- Hongbo Lui,
- Bingshu Chen,
- Deb Kellar,
- Irene Li,
- Sung-Eun Lee,
- Takako Kono,
- Brian Y. C. Cheng,
- Damian Yap,
- Daniel Lai,
- Sean Beatty,
- John Soong,
- Kathleen I. Pritchard,
- Isabel Soria-Bretones,
- Eric Chen,
- Harriet Feilotter,
- Moira Rushton,
- Lesley Seymour,
- Samuel Aparicio,
- David W. Cescon
Affiliations
- John Hilton
- Ottawa Hospital Research Institute
- Karen Gelmon
- BC Cancer - Vancouver Centre
- Philippe L. Bedard
- Princess Margaret Cancer Centre, University Health Network
- Dongsheng Tu
- Canadian Cancer Trials Group
- Hong Xu
- Molecular Oncology, BC Cancer Research Institute
- Anna V. Tinker
- BC Cancer - Vancouver Centre
- Rachel Goodwin
- Ottawa Hospital Research Institute
- Scott A. Laurie
- Ottawa Hospital Research Institute
- Derek Jonker
- Ottawa Hospital Research Institute
- Aaron R. Hansen
- Princess Margaret Cancer Centre, University Health Network
- Zachary W. Veitch
- Princess Margaret Cancer Centre, University Health Network
- Daniel J. Renouf
- BC Cancer - Vancouver Centre
- Linda Hagerman
- Canadian Cancer Trials Group
- Hongbo Lui
- Canadian Cancer Trials Group
- Bingshu Chen
- Canadian Cancer Trials Group
- Deb Kellar
- Ottawa Hospital Research Institute
- Irene Li
- Princess Margaret Cancer Centre, University Health Network
- Sung-Eun Lee
- BC Cancer - Vancouver Centre
- Takako Kono
- Molecular Oncology, BC Cancer Research Institute
- Brian Y. C. Cheng
- Molecular Oncology, BC Cancer Research Institute
- Damian Yap
- Molecular Oncology, BC Cancer Research Institute
- Daniel Lai
- Molecular Oncology, BC Cancer Research Institute
- Sean Beatty
- Molecular Oncology, BC Cancer Research Institute
- John Soong
- Senhwa Biosciences, Inc
- Kathleen I. Pritchard
- Sunnybrook Health Sciences Centre
- Isabel Soria-Bretones
- Princess Margaret Cancer Centre, University Health Network
- Eric Chen
- Princess Margaret Cancer Centre, University Health Network
- Harriet Feilotter
- Canadian Cancer Trials Group
- Moira Rushton
- Canadian Cancer Trials Group
- Lesley Seymour
- Canadian Cancer Trials Group
- Samuel Aparicio
- Molecular Oncology, BC Cancer Research Institute
- David W. Cescon
- Princess Margaret Cancer Centre, University Health Network
- DOI
- https://doi.org/10.1038/s41467-022-31199-2
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
G-quadruplex stabilizers, including CX-5461, exhibit synthetic lethality with loss of BRCA1/2 in preclinical models. Here the authors report the results of a phase I study of CX-5461 in patients with solid tumors enriched for DNA-repair deficiencies.
